Some of the novel drug discovery research findings made by Dr Reddy's Research Centre at Atlanta have been selected for presentation at the American Heart Association's annual scientific sessions being held at Chicago from November 17 to 21.

Dr Reddy's said in a press release in Hyderabad that these sessions would be participated by over 10,000 scientists and would unveil cutting-edge research in cardiovascular disease through oral and poster presentations.

Dr Reddy's presentation would be delivered in a special Featured Research Oral Session titled, "Intrinsic and Therapeutic Regulation of Intimal Hyperplasia" on November 20. Dr Reddy's presentation would showcase the role of an intracellular signaling protein in uncontrolled smooth muscle proliferation, a process that triggers cardiovascular disorders, including retenosis and atherosclerosis. It would also make an oral presentation at the same meeting on November 18. This presentation would highlight the role of the intracellular signaling protein in the expression of pro-inflammatory genes. Aberrent expression of these genes results in the progression of a number of inflammatory diseases, including atherosclerosis, arthritis, inflammatory bowel disease, septic shock and asthma.

Dr Reddy's is currently using these and other proprietary findings on this protein to design small organic molecules as potential novel anti-inflammatory and anti-proliferative drugs.

Dr Reddy's drug discovery effort is orchestrated through its state-of-the-art research facilities in Atlanta and Hyderabad. The Atlanta team uses genomics-based approaches for discovering new targets and NCEs in the areas of atherosclerosis, retenosis, diabetic nephropathy and arthiritis. The drug discovery programme in Hyderabad focuses on cancer, inflammation, bacterial infections and metabolic disorders with emphasis on Type 2 diabetes, dyslipidemia and obesity.

Dr Reddy's research facility currently has three molecules in clinical development and seven molecules in pre-clinical development.